A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 11, Pages 3041-3050
Publisher
Wiley
Online
2016-10-17
DOI
10.1002/cam4.862
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
- (2015) R. J. Sullivan et al. ONCOLOGIST
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
- (2014) Chang Xia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
- (2013) F Lai et al. Cell Death & Disease
- Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
- (2012) Jueng Soo You et al. CANCER CELL
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
- (2010) Tatiana Akimova et al. CLINICAL IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
- (2008) Satoru Yokoyama et al. Pigment Cell & Melanoma Research
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started